Intermune plots another Phase III for pirfenidone

Intermune ($ITMN) says it will begin enrollment of another late-stage trial of idiopathic pulmonary fibrosis drug pirfenidone in the first half of 2011. Eight months ago, the FDA rejected the company's application for approval, noting that another trial would be necessary if the company ever hopes to sell the drug in the U.S. Intermune has seen success in Europe, however, where a panel of experts issued a positive opinion of the drug in late 2010. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.